– Latest Outcomes From HIV Prevention and Treatment Clinical Research, Including Data From Pivotal Phase 3 PURPOSE 1 & 2 Trials –
– Real World Evidence in COVID-19 Reinforce Veklury (remdesivir) as the Antiviral Standard of Care for the Treatment of People Hospitalized for COVID-19 –
– Investigational Obeldesivir Safety and Tolerability Data From BIRCH and OAKTREE Trials Support Continued Evaluation as a Potential Treatment Option for RSV –
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31 presentations across HIV treatment and prevention, COVID-19 and viral hepatitis include one late breaker abstract and six oral presentations, reflecting Gilead's commitment to helping address the evolving needs of a diverse range of people and communities affected by some of the world's most challenging viruses.
